JP2018521962A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521962A5 JP2018521962A5 JP2017556861A JP2017556861A JP2018521962A5 JP 2018521962 A5 JP2018521962 A5 JP 2018521962A5 JP 2017556861 A JP2017556861 A JP 2017556861A JP 2017556861 A JP2017556861 A JP 2017556861A JP 2018521962 A5 JP2018521962 A5 JP 2018521962A5
- Authority
- JP
- Japan
- Prior art keywords
- tissue
- stem cell
- use according
- cancer tissue
- teratogenic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 210000001519 tissue Anatomy 0.000 claims 53
- 210000000130 stem cell Anatomy 0.000 claims 45
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000003795 chemical substances by application Substances 0.000 claims 24
- 230000024245 cell differentiation Effects 0.000 claims 23
- 231100000378 teratogenic Toxicity 0.000 claims 13
- 230000003390 teratogenic effect Effects 0.000 claims 13
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 claims 10
- 102000004270 Peptidyl-Dipeptidase A Human genes 0.000 claims 10
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 claims 10
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 claims 10
- 102000018651 Epithelial Cell Adhesion Molecule Human genes 0.000 claims 8
- 108010066687 Epithelial Cell Adhesion Molecule Proteins 0.000 claims 8
- OHCQJHSOBUTRHG-KGGHGJDLSA-N FORSKOLIN Chemical compound O=C([C@@]12O)C[C@](C)(C=C)O[C@]1(C)[C@@H](OC(=O)C)[C@@H](O)[C@@H]1[C@]2(C)[C@@H](O)CCC1(C)C OHCQJHSOBUTRHG-KGGHGJDLSA-N 0.000 claims 8
- RTRQQBHATOEIAF-UUOKFMHZSA-N acadesine Chemical group NC1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 RTRQQBHATOEIAF-UUOKFMHZSA-N 0.000 claims 8
- 239000003007 chemical teratogen Substances 0.000 claims 8
- 230000001066 destructive effect Effects 0.000 claims 8
- DSMXVSGJIDFLKP-UHFFFAOYSA-N n-[1-(4-chloroanilino)-1-oxopropan-2-yl]oxy-3,5-bis(trifluoromethyl)benzamide Chemical compound C=1C=C(Cl)C=CC=1NC(=O)C(C)ONC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 DSMXVSGJIDFLKP-UHFFFAOYSA-N 0.000 claims 8
- 230000037361 pathway Effects 0.000 claims 8
- 206010028980 Neoplasm Diseases 0.000 claims 7
- 201000011510 cancer Diseases 0.000 claims 7
- 239000000955 prescription drug Substances 0.000 claims 7
- 125000003349 3-pyridyl group Chemical group N1=C([H])C([*])=C([H])C([H])=C1[H] 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- SGKRLCUYIXIAHR-AKNGSSGZSA-N (4s,4ar,5s,5ar,6r,12ar)-4-(dimethylamino)-1,5,10,11,12a-pentahydroxy-6-methyl-3,12-dioxo-4a,5,5a,6-tetrahydro-4h-tetracene-2-carboxamide Chemical compound C1=CC=C2[C@H](C)[C@@H]([C@H](O)[C@@H]3[C@](C(O)=C(C(N)=O)C(=O)[C@H]3N(C)C)(O)C3=O)C3=C(O)C2=C1O SGKRLCUYIXIAHR-AKNGSSGZSA-N 0.000 claims 5
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 5
- KCIMKTNQCUDTFI-UHFFFAOYSA-N 4-fluoro-n-[5-fluoro-6-(5-methoxypyrazolo[1,5-a]pyridin-3-yl)-1h-pyrazolo[3,4-b]pyridin-3-yl]benzamide Chemical compound C=12C=C(OC)C=CN2N=CC=1C(C(=CC=12)F)=NC=1NN=C2NC(=O)C1=CC=C(F)C=C1 KCIMKTNQCUDTFI-UHFFFAOYSA-N 0.000 claims 5
- SHGAZHPCJJPHSC-NUEINMDLSA-N Isotretinoin Chemical compound OC(=O)C=C(C)/C=C/C=C(C)C=CC1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-NUEINMDLSA-N 0.000 claims 5
- CXOFVDLJLONNDW-UHFFFAOYSA-N Phenytoin Chemical compound N1C(=O)NC(=O)C1(C=1C=CC=CC=1)C1=CC=CC=C1 CXOFVDLJLONNDW-UHFFFAOYSA-N 0.000 claims 5
- 239000004098 Tetracycline Substances 0.000 claims 5
- 239000003098 androgen Substances 0.000 claims 5
- CFOYWRHIYXMDOT-UHFFFAOYSA-N carbimazole Chemical compound CCOC(=O)N1C=CN(C)C1=S CFOYWRHIYXMDOT-UHFFFAOYSA-N 0.000 claims 5
- 229960001704 carbimazole Drugs 0.000 claims 5
- NIJJYAXOARWZEE-UHFFFAOYSA-N di-n-propyl-acetic acid Natural products CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 229960003722 doxycycline Drugs 0.000 claims 5
- 239000003814 drug Substances 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 229960005280 isotretinoin Drugs 0.000 claims 5
- 229960004942 lenalidomide Drugs 0.000 claims 5
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 5
- 229960002036 phenytoin Drugs 0.000 claims 5
- 229960005322 streptomycin Drugs 0.000 claims 5
- 229960002180 tetracycline Drugs 0.000 claims 5
- 229930101283 tetracycline Natural products 0.000 claims 5
- 235000019364 tetracycline Nutrition 0.000 claims 5
- 150000003522 tetracyclines Chemical class 0.000 claims 5
- 229960003433 thalidomide Drugs 0.000 claims 5
- ZEMGGZBWXRYJHK-UHFFFAOYSA-N thiouracil Chemical compound O=C1C=CNC(=S)N1 ZEMGGZBWXRYJHK-UHFFFAOYSA-N 0.000 claims 5
- 229950000329 thiouracil Drugs 0.000 claims 5
- MSRILKIQRXUYCT-UHFFFAOYSA-M valproate semisodium Chemical compound [Na+].CCCC(C(O)=O)CCC.CCCC(C([O-])=O)CCC MSRILKIQRXUYCT-UHFFFAOYSA-M 0.000 claims 5
- 229960000604 valproic acid Drugs 0.000 claims 5
- 125000004211 3,5-difluorophenyl group Chemical group [H]C1=C(F)C([H])=C(*)C([H])=C1F 0.000 claims 4
- NMUSYJAQQFHJEW-UHFFFAOYSA-N 5-Azacytidine Natural products O=C1N=C(N)N=CN1C1C(O)C(O)C(CO)O1 NMUSYJAQQFHJEW-UHFFFAOYSA-N 0.000 claims 4
- NMUSYJAQQFHJEW-KVTDHHQDSA-N 5-azacytidine Chemical compound O=C1N=C(N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 NMUSYJAQQFHJEW-KVTDHHQDSA-N 0.000 claims 4
- RTRQQBHATOEIAF-UHFFFAOYSA-N AICA riboside Natural products NC1=C(C(=O)N)N=CN1C1C(O)C(O)C(CO)O1 RTRQQBHATOEIAF-UHFFFAOYSA-N 0.000 claims 4
- 102100024222 B-lymphocyte antigen CD19 Human genes 0.000 claims 4
- 206010004146 Basal cell carcinoma Diseases 0.000 claims 4
- 206010006187 Breast cancer Diseases 0.000 claims 4
- 208000026310 Breast neoplasm Diseases 0.000 claims 4
- 102000011727 Caspases Human genes 0.000 claims 4
- 108010076667 Caspases Proteins 0.000 claims 4
- 206010009944 Colon cancer Diseases 0.000 claims 4
- QASFUMOKHFSJGL-LAFRSMQTSA-N Cyclopamine Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H](CC2=C3C)[C@@H]1[C@@H]2CC[C@@]13O[C@@H]2C[C@H](C)CN[C@H]2[C@H]1C QASFUMOKHFSJGL-LAFRSMQTSA-N 0.000 claims 4
- DWJXYEABWRJFSP-XOBRGWDASA-N DAPT Chemical compound N([C@@H](C)C(=O)N[C@H](C(=O)OC(C)(C)C)C=1C=CC=CC=1)C(=O)CC1=CC(F)=CC(F)=C1 DWJXYEABWRJFSP-XOBRGWDASA-N 0.000 claims 4
- SUZLHDUTVMZSEV-UHFFFAOYSA-N Deoxycoleonol Natural products C12C(=O)CC(C)(C=C)OC2(C)C(OC(=O)C)C(O)C2C1(C)C(O)CCC2(C)C SUZLHDUTVMZSEV-UHFFFAOYSA-N 0.000 claims 4
- 102100033189 Diablo IAP-binding mitochondrial protein Human genes 0.000 claims 4
- 101000980825 Homo sapiens B-lymphocyte antigen CD19 Proteins 0.000 claims 4
- 102100033421 Keratin, type I cytoskeletal 18 Human genes 0.000 claims 4
- 108010066327 Keratin-18 Proteins 0.000 claims 4
- 206010033128 Ovarian cancer Diseases 0.000 claims 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims 4
- 206010060862 Prostate cancer Diseases 0.000 claims 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims 4
- 101710187743 Tumor necrosis factor receptor superfamily member 1A Proteins 0.000 claims 4
- 102100033732 Tumor necrosis factor receptor superfamily member 1A Human genes 0.000 claims 4
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims 4
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 claims 4
- IMOZEMNVLZVGJZ-QGZVFWFLSA-N apremilast Chemical compound C1=C(OC)C(OCC)=CC([C@@H](CS(C)(=O)=O)N2C(C3=C(NC(C)=O)C=CC=C3C2=O)=O)=C1 IMOZEMNVLZVGJZ-QGZVFWFLSA-N 0.000 claims 4
- 229960001164 apremilast Drugs 0.000 claims 4
- 229960002756 azacitidine Drugs 0.000 claims 4
- OHCQJHSOBUTRHG-UHFFFAOYSA-N colforsin Natural products OC12C(=O)CC(C)(C=C)OC1(C)C(OC(=O)C)C(O)C1C2(C)C(O)CCC1(C)C OHCQJHSOBUTRHG-UHFFFAOYSA-N 0.000 claims 4
- 208000029742 colonic neoplasm Diseases 0.000 claims 4
- QASFUMOKHFSJGL-UHFFFAOYSA-N cyclopamine Natural products C1C=C2CC(O)CCC2(C)C(CC2=C3C)C1C2CCC13OC2CC(C)CNC2C1C QASFUMOKHFSJGL-UHFFFAOYSA-N 0.000 claims 4
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 claims 4
- 229960003957 dexamethasone Drugs 0.000 claims 4
- RGLYKWWBQGJZGM-ISLYRVAYSA-N diethylstilbestrol Chemical compound C=1C=C(O)C=CC=1C(/CC)=C(\CC)C1=CC=C(O)C=C1 RGLYKWWBQGJZGM-ISLYRVAYSA-N 0.000 claims 4
- 238000011977 dual antiplatelet therapy Methods 0.000 claims 4
- 206010017758 gastric cancer Diseases 0.000 claims 4
- 208000005017 glioblastoma Diseases 0.000 claims 4
- 201000010536 head and neck cancer Diseases 0.000 claims 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims 4
- 201000001441 melanoma Diseases 0.000 claims 4
- 201000002528 pancreatic cancer Diseases 0.000 claims 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims 4
- 229930002330 retinoic acid Natural products 0.000 claims 4
- 206010041823 squamous cell carcinoma Diseases 0.000 claims 4
- 201000011549 stomach cancer Diseases 0.000 claims 4
- SJMDMGHPMLKLHQ-UHFFFAOYSA-N tert-butyl 2-aminoacetate Chemical compound CC(C)(C)OC(=O)CN SJMDMGHPMLKLHQ-UHFFFAOYSA-N 0.000 claims 4
- 229960001727 tretinoin Drugs 0.000 claims 4
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 claims 3
- 102100032912 CD44 antigen Human genes 0.000 claims 3
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 claims 3
- 101000868273 Homo sapiens CD44 antigen Proteins 0.000 claims 3
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 claims 3
- 101000884271 Homo sapiens Signal transducer CD24 Proteins 0.000 claims 3
- 101000800116 Homo sapiens Thy-1 membrane glycoprotein Proteins 0.000 claims 3
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 3
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 3
- CDKIEBFIMCSCBB-CALJPSDSSA-N SIS3 Chemical compound Cl.C1C=2C=C(OC)C(OC)=CC=2CCN1C(=O)\C=C\C(C1=CC=CN=C1N1C)=C1C1=CC=CC=C1 CDKIEBFIMCSCBB-CALJPSDSSA-N 0.000 claims 3
- 102100038081 Signal transducer CD24 Human genes 0.000 claims 3
- 101150052863 THY1 gene Proteins 0.000 claims 3
- 102100033523 Thy-1 membrane glycoprotein Human genes 0.000 claims 3
- 230000003213 activating effect Effects 0.000 claims 3
- 229960003896 aminopterin Drugs 0.000 claims 3
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 3
- -1 desmocholine-2 Proteins 0.000 claims 3
- 201000005202 lung cancer Diseases 0.000 claims 3
- 208000020816 lung neoplasm Diseases 0.000 claims 3
- 229960000485 methotrexate Drugs 0.000 claims 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 102100027308 Apoptosis regulator BAX Human genes 0.000 claims 2
- 108050006685 Apoptosis regulator BAX Proteins 0.000 claims 2
- 102100021569 Apoptosis regulator Bcl-2 Human genes 0.000 claims 2
- 108700020463 BRCA1 Proteins 0.000 claims 2
- 101150072950 BRCA1 gene Proteins 0.000 claims 2
- 101150017888 Bcl2 gene Proteins 0.000 claims 2
- 102100025401 Breast cancer type 1 susceptibility protein Human genes 0.000 claims 2
- 102000004178 Cathepsin E Human genes 0.000 claims 2
- 108090000611 Cathepsin E Proteins 0.000 claims 2
- 102000003727 Caveolin 1 Human genes 0.000 claims 2
- 108090000026 Caveolin 1 Proteins 0.000 claims 2
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 claims 2
- 101150082208 DIABLO gene Proteins 0.000 claims 2
- 102000005721 Death-Associated Protein Kinases Human genes 0.000 claims 2
- 108010031042 Death-Associated Protein Kinases Proteins 0.000 claims 2
- 101710101225 Diablo IAP-binding mitochondrial protein Proteins 0.000 claims 2
- 101710156605 Diablo homolog, mitochondrial Proteins 0.000 claims 2
- 108010045100 HSP27 Heat-Shock Proteins Proteins 0.000 claims 2
- 102100039165 Heat shock protein beta-1 Human genes 0.000 claims 2
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 claims 2
- 101000979001 Homo sapiens Methionine aminopeptidase 2 Proteins 0.000 claims 2
- 101000969087 Homo sapiens Microtubule-associated protein 2 Proteins 0.000 claims 2
- 101000623901 Homo sapiens Mucin-16 Proteins 0.000 claims 2
- 101001024605 Homo sapiens Next to BRCA1 gene 1 protein Proteins 0.000 claims 2
- 101000874179 Homo sapiens Syndecan-1 Proteins 0.000 claims 2
- 102100040445 Keratin, type I cytoskeletal 14 Human genes 0.000 claims 2
- 102100040443 Keratin, type I cytoskeletal 15 Human genes 0.000 claims 2
- 102100025756 Keratin, type II cytoskeletal 5 Human genes 0.000 claims 2
- 102100023972 Keratin, type II cytoskeletal 8 Human genes 0.000 claims 2
- 108010066321 Keratin-14 Proteins 0.000 claims 2
- 108010066330 Keratin-15 Proteins 0.000 claims 2
- 108010070553 Keratin-5 Proteins 0.000 claims 2
- 108010070511 Keratin-8 Proteins 0.000 claims 2
- 108010060408 Member 25 Tumor Necrosis Factor Receptors Proteins 0.000 claims 2
- 102000008166 Member 25 Tumor Necrosis Factor Receptors Human genes 0.000 claims 2
- 102100023174 Methionine aminopeptidase 2 Human genes 0.000 claims 2
- 102100034256 Mucin-1 Human genes 0.000 claims 2
- 108010008707 Mucin-1 Proteins 0.000 claims 2
- 102100023123 Mucin-16 Human genes 0.000 claims 2
- 101001092200 Mus musculus RNA binding protein fox-1 homolog 3 Proteins 0.000 claims 2
- 101710150336 Protein Rex Proteins 0.000 claims 2
- 102100035721 Syndecan-1 Human genes 0.000 claims 2
- 108010000449 TNF-Related Apoptosis-Inducing Ligand Receptors Proteins 0.000 claims 2
- 102000002259 TNF-Related Apoptosis-Inducing Ligand Receptors Human genes 0.000 claims 2
- 102000004243 Tubulin Human genes 0.000 claims 2
- 108090000704 Tubulin Proteins 0.000 claims 2
- 239000012190 activator Substances 0.000 claims 2
- 230000005775 apoptotic pathway Effects 0.000 claims 2
- 108010052621 fas Receptor Proteins 0.000 claims 2
- 102000018823 fas Receptor Human genes 0.000 claims 2
- 230000036244 malformation Effects 0.000 claims 2
- 210000003470 mitochondria Anatomy 0.000 claims 2
- 102000004401 podocalyxin Human genes 0.000 claims 2
- 108090000917 podocalyxin Proteins 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 239000003439 teratogenic agent Substances 0.000 claims 2
- 102100032202 Cornulin Human genes 0.000 claims 1
- 101710148705 Cornulin Proteins 0.000 claims 1
- 102100040481 Desmocollin-2 Human genes 0.000 claims 1
- 101710157873 Desmocollin-2 Proteins 0.000 claims 1
- 230000002886 autophagic effect Effects 0.000 claims 1
- 230000004642 autophagic pathway Effects 0.000 claims 1
- 230000004069 differentiation Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 230000001613 neoplastic effect Effects 0.000 claims 1
- 230000008520 organization Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562155459P | 2015-04-30 | 2015-04-30 | |
| US62/155,459 | 2015-04-30 | ||
| PCT/US2016/030391 WO2016176675A2 (en) | 2015-04-30 | 2016-05-02 | Patient treatment via teratogenic pharmaceutical compounds |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2018521962A JP2018521962A (ja) | 2018-08-09 |
| JP2018521962A5 true JP2018521962A5 (enExample) | 2019-05-30 |
Family
ID=57199606
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017556861A Pending JP2018521962A (ja) | 2015-04-30 | 2016-05-02 | 催奇形性医薬化合物を介した患者処置 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US11000536B2 (enExample) |
| JP (1) | JP2018521962A (enExample) |
| CN (1) | CN108366987A (enExample) |
| AU (1) | AU2016255577A1 (enExample) |
| CA (1) | CA2990861A1 (enExample) |
| WO (1) | WO2016176675A2 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2016255577A1 (en) | 2015-04-30 | 2018-11-15 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
| EP4065550B1 (en) * | 2019-11-25 | 2024-09-04 | Westlake University | Aminoxy acid-based anti-cancer stem cell compounds and methods thereof |
| TW202214244A (zh) * | 2020-08-10 | 2022-04-16 | 國立彰化師範大學 | 具有協同抗癌功效之氯硝柳胺（Ｎｉｃｌｏｓａｍｉｄｅ）和雙硫侖（Ｄｉｓｕｌｆｉｒａｍ）醫藥組合物及其用途 |
| CN112462065A (zh) * | 2020-11-16 | 2021-03-09 | 浙江博真生物科技有限公司 | 一种用于检测实体肿瘤的抗体组合物、试剂盒及检测方法 |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2672000C (en) * | 2002-05-17 | 2011-11-29 | Celgene Corporation | Methods and compositions using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for treatment and management of lymphoma |
| CN1852974A (zh) * | 2003-06-09 | 2006-10-25 | 密歇根大学董事会 | 用于治疗和诊断癌症的组合物和方法 |
| AU2004256425A1 (en) * | 2003-06-09 | 2005-01-20 | The Regents Of The University Of Michigan | Compositions and methods for treating and diagnosing cancer |
| ITRM20040438A1 (it) | 2004-09-15 | 2004-12-15 | Univ Palermo | Metodo per la purificazione e l'amplificazione di cellule staminali tumorali. |
| EP2676678A1 (en) * | 2007-07-17 | 2013-12-25 | The General Hospital Corporation | Methods to identify and enrich populations of ovarian cancer stem cells and somatic stem cells and uses thereof |
| EP2429584A4 (en) * | 2009-05-13 | 2013-02-20 | Genzyme Corp | TREATMENT PROCEDURE AND COMPOSITIONS |
| CA2771190C (en) * | 2009-08-17 | 2020-01-21 | Memorial Sloan-Kettering Cancer Center | Heat shock protein binding compounds, compositions, and methods for making and using same |
| AU2011255218B2 (en) * | 2010-05-21 | 2015-03-12 | Infinity Pharmaceuticals, Inc. | Chemical compounds, compositions and methods for kinase modulation |
| EP2704699A1 (en) * | 2011-05-03 | 2014-03-12 | University of Rochester | Methods for treating prostate cancer |
| JP6470687B2 (ja) * | 2012-09-03 | 2019-02-13 | ノヴォ ノルディスク アー／エス | 小分子を用いた多能性幹細胞からの膵臓内胚葉の作製 |
| AU2013331154B2 (en) * | 2012-10-17 | 2018-02-01 | Cedars-Sinai Medical Center | Molecular signatures of ovarian cancer |
| AU2016255577A1 (en) | 2015-04-30 | 2018-11-15 | Nant Holdings Ip, Llc | Patient treatment via teratogenic pharmaceutical compounds |
-
2016
- 2016-05-02 AU AU2016255577A patent/AU2016255577A1/en not_active Abandoned
- 2016-05-02 CA CA2990861A patent/CA2990861A1/en not_active Abandoned
- 2016-05-02 US US15/570,733 patent/US11000536B2/en active Active
- 2016-05-02 CN CN201680039086.6A patent/CN108366987A/zh active Pending
- 2016-05-02 JP JP2017556861A patent/JP2018521962A/ja active Pending
- 2016-05-02 WO PCT/US2016/030391 patent/WO2016176675A2/en not_active Ceased
-
2020
- 2020-09-16 US US17/022,560 patent/US12016872B2/en active Active
-
2024
- 2024-03-13 US US18/604,108 patent/US20240216409A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Modesitt et al. | A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study | |
| JP2018521962A5 (enExample) | ||
| JP2023513015A (ja) | 異常な細胞成長を処置するための併用療法 | |
| Hoffe et al. | Cancer and age: general considerations | |
| JP2022113886A (ja) | 異常な細胞成長を処置するための方法および組成物 | |
| Joung et al. | Combination of AG490, a Jak2 inhibitor, and methylsulfonylmethane synergistically suppresses bladder tumor growth via the Jak2/STAT3 pathway | |
| HRP20220619T1 (hr) | Postupci za liječenje ar+ raka dojke | |
| Sharma et al. | Induction of CXCR2 ligands, stem cell-like phenotype, and metastasis in chemotherapy-resistant breast cancer cells | |
| WO2014072493A1 (en) | Pharmaceutical combination comprising a b-raf inhibitor and a histone deacetylase inhibitor and their use in the treatment of proliferative diseases | |
| JP2018519324A5 (enExample) | ||
| KR20170058432A (ko) | 상승 효과적 아우리스타틴 조합 | |
| RU2754452C2 (ru) | Комбинированная терапия ингибиторами notch и pi3k/mtor для применения в лечении рака | |
| WO2015097622A1 (en) | Pharmaceutical combinations | |
| EP4142882A1 (en) | Methods of treating abnormal cell growth | |
| Sharmin et al. | Cytotoxicity of synthetic derivatives against breast cancer and multi-drug resistant breast cancer cell lines: A literature-based perspective study | |
| KR20150042231A (ko) | 소세포폐암을 치료하기 위한 벤조디아제핀 | |
| US12016872B2 (en) | Patient treatment via teratogenic pharmaceutical compounds | |
| JP2014532648A5 (enExample) | ||
| TW201138764A (en) | Anticancer combinations of artemisinin-based drugs and other chemotherapeutic agents | |
| UA121392C2 (uk) | Комбінація, яка містить глюкокортикоїд і edo-s101 | |
| Bogado et al. | BI 6727 and GSK461364 suppress growth and radiosensitize osteosarcoma cells, but show limited cytotoxic effects when combined with conventional treatments | |
| JP2013536243A (ja) | 癌の治療に有用なｖｅｇｆｒ阻害剤およびｍｅｋ阻害剤の医薬的組み合わせ | |
| JP2022532766A (ja) | 家族性腺腫性ポリポーシスを処置するための方法 | |
| Zhao et al. | Enhancement of histone deacetylase inhibitor sensitivity in combination with cyclin-dependent kinase inhibition for the treatment of oral squamous cell carcinoma | |
| JP2005506366A (ja) | 選択的シクロオキシゲナーゼ−２阻害剤を含む組合せ剤 |